Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay

Clinical and Vaccine Immunology

Volumn 13, Issue 6, 2006, Pages 684-697

  Samri, A ^a   Durier, C ^b   Urrutia, A ^c   Sanchez, I ^b   Gahery Segard, H ^d   Imbart, S ^e   Sinet, M ^c   Tartour, E ^e   Aboulker, J P ^b   Autran, B ^a   Venet, A ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d Hôpital Cochin ^*  (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA VIRUS A; INTERMETHOD COMPARISON; LABORATORY TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE;

ANTIBODIES; CLUSTER ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; PEPTIDES; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES;

EID: 33745855139     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00387-05     Document Type: Article

References (58)

1. AIDS Vaccine Evaluation Group 022 Protocol Team. 2001. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183:563-570.
2. Alatrakchi, N., V. Di Martino, V. Thibault, and B. Autran. 2002. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 16:713-717,
3. Alatrakchi, N., C. Duvivier, D. Costagliola, A. Samri, A. G. Marcelin, G. Karakamidze, M. Astriti, R. Agher, V. Calvez, B. Autran, and C. Katlama. 2005. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19:25-33.
4. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96. (Erratum, 280:1821.)
5. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991.
6. Bieganowska, K., P. Hollsberg, G. J. Buckle, D. G. Lim, T. F. Greten, J. Schneck, J. D. Altman, S. Jacobson, S. L. Ledis, B. Hanchard, J. Chin, O. Morgan, P. A. Roth, and D. A. Hafler. 1999. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol. 162:1765-1771.
7. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310.
8. Callan, M. F., L. Tan, N. Annels, G. S. Ogg, J. D. Wilson, C. A. O'Callaghan, N. Steven, A. J. McMichael, and A. B. Rickinson. 1998. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395-1402.
9. Carcelain, G., R. Tubiana, A. Samri, V. Calvez, C. Delaugerre, H. Agut, C. Katlama, and B. Autran. 2001. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 75:234-241.
10. Combadiere, B., A. Boissonnas, G. Carcelain, E. Lefranc, A. Samri, F. Bricaire, P. Debre, and B. Autran. 2004. Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J. Exp. Med. 199:1585-1593.
11. Cox, J. H., G. Ferrari, S. A. Kalams, W. Lopaczynski, N. Oden, M. P. D'Souza, et al. 2005. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retrovir. 21:68-81.
12. Czerkinsky, C., G. Andersson, H. P. Ekre, L. A. Nilsson, L. Klareskog, and O. Ouchterlony. 1988. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110:29-36.
13. Doisne, J. M., A. Urrutia, C. Lacabaratz-Porret, C. Goujard, L. Meyer, M. L. Chaix, M. Sinet, and A. Venet. 2004. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J. Immunol. 173:2410-2418.
14. Draenert, R., C. Verrill, Y. Tang, T. Allen, A. Wurcel, M. Boczanowski, A. Lechner, A. Kim, T. Suscovich, N. Brown, M. Addo, and B. Walker. 2004. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 2:630-641.
15. Engstrand, M., C. Tournay, M. A. Peyrat, B. M. Erikssun, J. Wadstrom, B. Z. Wirgart, F. Romagne, M. Bonneville, T. H. Totterman, and O. Korsgren. 2000. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 69:2243-2250.
16. Ewer, K., J. Deeks, L. Alvarez, G. Bryant, S. Waller, P. Andersen, P. Monk, and A. Lalvani. 2003. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361:1168-1173.
17. Froebel, K. S., N. G. Pakker, F. Aiuti, M. Bofill, H. Choremi-Papadopoulou, J. Economidou, C. Rabian, M. T. Roos, L. P. Ryder, F. Miedema, G. M. Raab, et al. 1999. Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. J. Immunol. Methods 227:85-97.
18. Gazagne, A., E. Claret, J. Wijdenes, H. Yssel, F. Bousquet, E. Levy, P. Vielh, F. Scotte, T. L. Goupil, W. H. Fridman, and E. Tartour. 2003. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J. Immunol. Methods 283:91-98.
19. Gray, C. M., J. Lawrence, J. M. Schapiro, J. D. Altman, M. A. Winters, M. Crompton, M. Loi, S. K. Kundu, M. M. Davis, and T. C. Merigan. 1999. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162:1780-1788.
20. Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103:966-972.
21. He, X. S., B. Rehermann, F. X. Lopez-Labrador, J. Boisvert, R. Cheung, J. Mumm, H. Wedemeyer, M. Berenguer, T. L. Wright, M. M. Davis, and H. B. Greenberg. 1999. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 96:5692-5697.
22. Hoen, B., I. Fournier, C. Lacabaratz, M. Burgard, I. Charreau, M. L. Chaix, J. M. Molina, J. M. Livrozet, A. Venet, F. Raffi, J. P. Aboulker, and C. Rouzioux. 2005. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J. Acquir. Immune Defic. Syndr. 40:307-316.
23. Hudgens, M. G., S. G. Self, Y. L. Chiu, N. D. Russell, H. Horton, and M. J. McElrath. 2004. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J. Immunol. Methods 288:19-34.
24. Israeli, E., R. Safadi, A. Melhem, O. Pappo, O. Shibolet, A. Klein, N. Hemed, B. Thalenfeld, D. Engelhardt, E. Rabbani, and Y. IIan. 2004. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int. 24:295-307.
25. Jeffery, K. J., K. Usuku, S. E. Hall, W. Matsumoto, G. P. Taylor, J. Procter, M. Bunce, G. S. Ogg, K. I. Welsh, J. N. Weber, A. L. Lloyd, M. A. Nowak, M. Nagai, D. Kodama, S. Izumo, M. Osame, and C. R. Bangham. 1999. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc. Natl. Acad. Sci. USA 96:3848-3853.
26. Karlsson, A. C., J. N. Martin, S. R. Younger, B. M. Bredt, L. Epling, R. Ronquillo, A. Varma, S. G. Deeks, J. M. McCune, D. F. Nixon, and E. Sinclair. 2003. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 283:141-153.
27. Kern, F., N. Faulhaber, C. Frommel, E. Khatamzas, S. Prosch, C. Schonemann, I. Kretzschmar, R. Volkmer-Engert, H. D. Volk, and P. Reinke. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30:1676-1682.
28. Kinloch-de Loes, S., B. Hoen, D. E. Smith, B. Autran, F. C. Lampe, A. N. Phillips, L. E. Goh, J. Andersson, C. Tsoukas, A. Sonnerborg, G. Tambussi, P. M. Girard, M. Bloch, M. Battegay, N. Carter, R. El Habib, G. Theofan, D. A. Cooper, and L. Perrin. 2005. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 192:607-617.
29. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373-1381.
30. Lacabaratz-Porret, C., B. Hoen, A. Urrutia, A. Rodallec, A. Compagnucci, M. Burgard, C. Rouzioux, A. Venet, et al. 2004. Abstr. 11th Conf. Retrovir. Opportunistic Infect., abstr. 168.
31. Lacabaratz-Porret, C., A. Urrutia, J. M. Doisne, C. Goujard, C. Deveau, M. Dalod, L. Meyer, C. Rouzioux, J. F. Delfraissy, A. Venet, and M. Sinet. 2003. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J. Infect. Dis. 187:748-757.
32. Lalvani, A., R. Brookes, S. Hambleton, W. J. Britton, A. V. Hill, and A. J. McMichael. 1997. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186:859-865.
33. Larsson, M., X. Jin, B. Ramratnam, G. S. Ogg, J. Engelmayer, M. A. Demoitie, A. J. McMichael, W. I. Cox, R. M. Steinman, D. Nixon, and N. Bhardwaj. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 13:767-777.
34. Larsson, M., D. Messmer, S. Somersan, J. F. Fonteneau, S. M. Donahoe, M. Lee, P. R. Dunbar, V. Cerundolo, I. Julknnen, D. F. Nixon, and N. Bhardwaj. 2000. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J. Immunol. 165:1182-1190.
35. Levy, Y., H. Gahery-Segard, C. Durier, A. S. Lascaux, C. Goujard, V. Meiffredy, C. Rouzioux, R. E. Habib, M. Beumont-Mauviel, J. G. Guillet, J. F. Delfraissy, and J. P. Aboulker. 2005. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19:279-286.
36. Lichterfeld, M., D. E. Kaufmann, X. G. Yu, S. K. Mui, M. M. Addo, M. N. Johnston, D. Cohen, G. K. Robbins, E. Pae, G. Alter, A. Wurcel, D. Stone, E. S. Rosenberg, B. D. Walker, and M. Altfield. 2004. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med. 6:701-712.
37. Maclure, M., and W. C. Willett. 1987. Misinterpretation and misuse of the kappa statistic. Am. J. Epidemiol. 126:161-169.
38. Maecker, H. T., H. S. Dunn, M. A. Suni, E. Khatamzas, C. J. Pitcher, T. Bunde, N. Persaud, W. Trigona, T. M. Fu, E. Sinclair, B. M. Bredt, J. M. McCune, V. C. Maino, F. Kern, and L. J. Picker. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40.
39. McElrath, M. 2004. Challenges in the monitoring of vaccine-induced T cell response. Presented at the AIDS Vaccine Oral, Plenary Sessions, Lausanne, Switzerland, 30 August to 1 September 2004.
40. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
41. Mwau, M., A. J. McMichael, and T. Hanke. 2002. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retrovir. 18:611-618.
42. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, J. S. Rowland, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
43. Ogg, G. S., and A. J. McMichael. 1999. Quantitation of antigen-specific CD8+ T-cell responses. Immunol. Lett. 66:77-80.
44. Ronnelid, J., and L. Klareskog. 1997. A comparison between ELISPOT methods for the detection of cytokine producing cells: greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes. J. Immunol. Methods 200:17-26.
45. Russell, N. D., M. G. Hudgens, R. Ha, C. Havenar-Daughton, and M. J. McElrath. 2003. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J. Infect. Dis. 187:226-242.
46. Samri, A., G. Haas, J. Duntze, J. M. Bouley, V. Calvez, C. Katlama, and B. Autran. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:9306-9312.
47. Scheibenbogen, C., P. Romero, L. Rivoltini, W. Herr, A. Schmittel, J. C. Cerottini, T. Woelfel, A. M. Eggermont, and U. Keilholz. 2000. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J. Immunol. Methods 244:81-89.
48. Schmittel, A., U. Keilholz, and C. Scheibenbogen. 1997. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 210:167-174.
49. Smith, J. G., X. Liu, R. M. Kaufhold, J. Clair, and M. J. Caulfield. 2001. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 8:871-879.
50. Sun, Y., E. Iglesias, A. Samri, G. Kamkamidze, T. Decoville, G. Carcelain, and B. Autran. 2003. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J. Immunol. Methods 272:23-34.
51. Tan, L. C., N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O'Callaghan, J. S. Rowland, A. J. McMichael, A. B. Rickinson, and M. F. Callan. 1999. A re-evaluation of the frequency of CDS + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
52. Tubiana, R., G. Carcelain, M. Vray, K. Gourlain, C. Dalban, A. Chermak, C. Rabian, D. Vittecoq, A. Simon, E. Bouvet, R. El Habib, D. Costagliola, V. Calvez, B. Autran, and C. Katlama. 2005. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter study (ANRS 094). Vaccine 23:4292-4301.
53. Whitby, L., V. Granger, I. Storie, K. Goodfellow, A. Sawle, J. T. Reilly, and D. Barnett. 2002. Quality control of CD4+ T-lymphocyte enumeration: results from the last 9 years of the United Kingdom National External Quality Assessment Scheme for Immune Monitoring (1993-2001). Cytometry 50:102-110.
54. Whiteside, T. L. 2000. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol. Investig. 29:149-162.
55. Whiteside, T. L. 2000. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin. Diagn. Lab. Immunol. 7:327-332.
56. Wilson, J. D., N. Imami, A. Watkins, J. Gill, P. Hay, B. Gazzard, M. Westby, and F. M. Gotch. 2000. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J. Infect. Dis. 182:792-798.
57. Wodarz, D., M. A. Nowak, and C. R. Bangham. 1999. The dynamics of HTLV-I and the CTL response. Immunol. Today 20:220-227.
58. Younes, S. A., B. Yassine-Diab, A. R. Dumont, M. R. Boulassel, Z. Grossman, J. P. Routy, and R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198:1909-1922.